Slide 1: H1 2025 Results
H1 2025 Results Matthias Gaertner, CEO Falk Neukirch, CFO August 13, 2025
Slide 2: Agenda: Executive summary
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix “We are creating the leading European Specialty Pharma platform to treat diseases optimally with individualized medicine.” Matthias Gärtner, CEO Medios AG 2
Slide 3: Highlights H1 2025
Executive summary Highlights H1 2025 H1 2025: Significant increase in profitability, strong organic EBITDA pre growth • Revenue up by 9.3% to €991.7m Financials • Disproportionate EBITDA pre increase to €46.3m (+48.8%); significant EBITDA pre margin expansion to 4.7%; 12.3% organic EBITDA pre growth
Slide 4: Successful AGM 2025 – Selected agenda items
Executive summary Successful AGM 2025 – Selected agenda items Approval of adjusted Compensation system for the Executive Board • Realignment of the Short-Term Incentive (STI) New financial KPI: Operational cash flow • Objective: stronger focus on operational performance indicators • Promotion of eff
Slide 5: QoQ – Revenue and EBITDA pre growth
Executive summary QoQ – Revenue and EBITDA pre growth Revenue (€m) EBITDA pre¹ (€m) 493 507 24.6 490 485 23.2 23.1 23.3 483 451 441 456 431 422 5 . 17.2 0 16.1 15.0 15.1 14.1 14.3 5.0 4.8 4.8 4.6 3.5 3.3 3.5 3.2 3.3 3.6 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2023 2024 2025 2023
Slide 6: YoY H1 2025 – Strong EBITDA pre margin improvement
Executive summary YoY H1 2025 – Strong EBITDA pre margin improvement Revenue in €m EBITDA pre¹ in €m 9.3% 48.8% 992 46.3 907 31.1 EBITDA pre1 4.7% margin 3.4% H1 2024 H1 2025 H1 2024 H1 2025 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization; EBITDA pr
Slide 7: Agenda: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix 7
Slide 8: H1 2025 – Solid Group financials
Financial overview H1 2025 – Solid Group financials In € million H1 2025 H1 2024 ∆ in % Comments Revenue 991.7 907.3 9.3% Revenue growth of 9.3% mainly driven by IB and PS Gross profit1 101.1 60.4 67.4% All operational segments contributed to the increase in gross margin in % 10. 2% 6.7% 3.4ppt prof
Slide 9: H1 2025 – Revenue growth driven by International Business
Financial overview H1 2025 – Revenue growth driven by International Business YoY Revenue in €m H1 24 Organic Inorganic H1 25 Comments Pharmaceutical Supply (PS) 787.9 12.2 - 800.1 • Inorganic growth attributable to Ceban (IB) acquisition Patient-Specific Therapies (PST) 107.5 2.7 - 110.2 • Organic g
Slide 10: H1 2025 – Strong EBITDA pre growth driven by all segments
Financial overview H1 2025 – Strong EBITDA pre growth driven by all segments YoY EBITDA pre1 in €m H1 24 Organic Inorganic H1 25 Comments Pharmaceutical Supply (PS) 22.9 3.5 - 26.4 • Significant organic growth of EBITDA pre by 12.3% driven by PS and PST Patient-Specific Therapies (PST) 10.9 1.2 - 12
Slide 11: H1 2025 – Substantial disproportionate EBITDA pre increase
Financial overview H1 2025 – Substantial disproportionate EBITDA pre increase Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million H1 25 H1 24 H1 25 H1 24 H1 25 H1 24 H1 25 H1 24 H1 25 H1 24 H1 25 H1 24 Segment rev
Slide 12: Financing Structure
Financial overview Financing Structure • New Syndicate loan concluded in Nov 2024 : €225m, consisting of • term loan of €125m, term: 5 yrs, annual redemption €25m starting March 25 and • Revolving credit facility (RCF) €100m (step-up option €50m), term 5 (+1 +1) yrs • Covenant based margin grid • Ne
Slide 13: Successful Share Buyback Offer
Financial overview Successful Share Buyback Offer • Offer Share buyback: Up to 1,000,000 bearer shares of current share Capital: €25,505,723 (approx. 3.92% ) • Offer price per share: €12.50 (Approx. +9.3% premium over the 5-day XETRA average closing price) • Authorization: Granted by the AGM on June
Slide 14: Agenda: Guidance 2025, strategy
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix “Medios delivers the best quality – reliably, competently and fast. These are key criteria for the optimal care of our patients.” 14
Slide 15: Disproportionate EBITDA pre increase expected
Guidance 2025 Disproportionate EBITDA pre increase expected Revenue (€bn) EBITDA pre1(€m) + 6.0% ~2.0 + 21.5% ~96 1.9 79 Margin ~4.8 (%) 4.2 2024 2025E* 2024 2025E* 1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization; EBITDA pre is adjusted for special
Slide 16: Clear strategy to build the leading European Specialty Pharma Platform
Strategy Clear strategy to build the leading European Specialty Pharma Platform Strengthening Expansion Diversification the Business in Europe Advanced in Germany Therapies Continue evolving out Expand compounding Become a trusted partner compounding infrastructure within Europe to gain for manufact
Slide 17: Agenda: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2025, strategy 4 Appendix “I am passionate about working for Medios because patient care is at the center of what we do.” 17
Slide 18: Ceban (IB) - Compounding value chain
Appendix Ceban (IB) - Compounding value chain Compounding Services API Services Pharmacies • Tailor-made medication • Sourcing, repacking and • 23 owned pharmacies across compounded at GMP-compliant distributing APIs and excipients the Netherlands under the facilities for pharmacies, to pharmacies a
Slide 19: ESG highlights 2025
Appendix ESG highlights 2025 Proportion of women We are committed to the 69% UN Global Compact Corporate Responsibility in workforce Initiative and its 0.1% 47% Customer complaint principles in the areas of human rights, labor, in management rate environment and anti- corruption 16 % 64% reduction S
Slide 20: Average to above-average ESG Ratings (August 2025)
Appendix Average to above-average ESG Ratings (August 2025) 0 62 100 Exceeds the industry benchmark D– C– A+ Top 15% in the Industry CCC AA AAA Top 43% in the Industry 0 34 100 Top 50% universe ranking 100 0 39 100 Top 13% in the Industry 100 15.4 0 Top 9% in the Industry (low risk) Source: Reports
Slide 21: Q2 2025 - Revenue growth driven by International Business
Appendix Q2 2025 - Revenue growth driven by International Business YoY Revenue in €m Q2 24 Organic Inorganic Q2 25 Comments Pharmaceutical Supply (PS) 386.9 24.0 - 410.9 • Inorganic growth driven by Ceban (IB) • Organic growth 6.4%: a result of strong Patient-Specific Therapies (PST) 52.5 2.0 - 54.5
Slide 22: Q2 2025 – Strong EBITDA pre growth driven by all segments
Appendix Q2 2025 – Strong EBITDA pre growth driven by all segments YoY EBITDA pre1 in €m Q2 24 Organic Inorganic Q2 25 Comments Pharmaceutical Supply (PS) 11.8 2.7 - 14.6 • Inorganic growth driven by Ceban (IB) • Strong organic growth of 19.6% driven Patient-Specific Therapies (PST) 4.9 0.8 - 5.7 by
Slide 23: Key figures (1/2)
Appendix Key figures (1/2) in € thousand H1 2025 H1 2024 ∆ in % Q2 2025 Q2 2024 ∆ in % Revenue 991,719 907,261 9.3% 507,055 451,036 12.4% Pharmaceutical Supply 800,109 787,930 1.5% 410,873 386,888 6.2% Patient-Specific Therapies 110,229 107,517 2.5% 54,467 52,456 3.8% International 81,144 11,584 >10
Slide 24: Key figures (2/2)
Appendix Key figures (2/2) in € thousand H1 2025 H1 2024 ∆ in % Q2 2025 Q2 2024 ∆ in % Earnings per share (in €) Undiluted 0.50 0.27 85.2% 0.25 0.10 >100% Diluted 0.50 0.27 85.2% 0.25 0.10 >100% Adjusted 2 0.96 0.72 34.1% 0.50 0.38 52.2% Investments (CAPEX) 2,884 1,784 61.7% 1,637 1,318 24.2% Cash f
Slide 25: Q2 2025 – Strong financials
Appendix Q2 2025 – Strong financials Pharmaceutical Patient-specific International Services IFRS Group Supply ‘PS‘ Therapies ‘PST’ Business ‘IB' consolidation YoY in € million Q2 25 Q2 24 Q2 25 Q2 24 Q2 25 Q2 24 Q2 25 Q2 24 Q2 25 Q2 24 Q2 25 Q2 24 Segment revenue – extern. 410.9 386.9 54.5 52.5 41.6
Slide 26: Total target remuneration
Appendix Remuneration System for the Total target remuneration Executive Board ESG Compensation structure of the total target remuneration Non-performance related fixed remuneration 28 – 35% Performance related remuneration 65 – 72% 1. Annual Short-Term-Incentive (STI) (target: 100%) 28 – 35%, STI t
Slide 27: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 Claudia.Nickolaus@medios.group
Slide 28: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 29: H1 2025 Results
H1 2025 Results Matthias Gaertner, CEO Falk Neukirch, CFO August 13, 2025